LP-590

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameLP-590
Drug Alias NameMulti-Kinase Inhibitors (Locus/Ansaris)LOC-K2LP-590LOC-K1LOC-G1
ClassificationSmall molecules
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsP38 α mitogen-activated protein kinase inhibitorsAngiogenesis inhibitors +[6] 
TargetsTyrosine-protein kinase receptor FLT3Vascular endothelial growth factor receptorP38 α mitogen-activated protein kinase +[4] 
Therapy Area/IndicationsInflammationBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLocus
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAnsaris IncLocus
Active IndicationsN/A
Inactive IndicationsInflammationBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A